Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults is a research paper published in Clinical Infectious Diseases (2023). On theSindex it has a DataRank of 0.671. It has been cited 16 times, with 13 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.425
From this paper's citation signal
Citation Network Contribution
0.246
From 8 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 13 citers.
Innovative Medicines Initiative 2 Joint Undertaking
Grant: 115854
Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854
ASPR HHS
Grant: HHSO100201700018C
Administration for Strategic Preparedness & Response
Merck Sharp & Dohme LLC
US Department of Health and Human Services
Bavarian Nordic
French Research Ministry
Biomedical Advanced Research and Development Authority
European Union’s Horizon 2020 research and innovation programme
National Institutes of Health
(NIH)
London School of Hygiene and Tropical Medicine
Janssen
EFPIA
Institut national de la santé et de la recherche médicale
Merck & Co., Inc.
FWCI
3.03
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals